Kodiak Sciences Announces Key Presentations for Investors
Kodiak Sciences Inc. (Nasdaq: KOD), a biotechnology company focused on transforming retina-related treatments, has some exciting news on the horizon. The company's Chief Executive Officer, Victor Perlroth, M.D., will present at significant upcoming investor conferences. This initiative aims to share their innovative progress in developing therapeutics that target major causes of blindness.
Upcoming Investor Conferences
Kodiak Sciences will have a presence at two notable investor events:
- Jefferies Global Healthcare Conference
- Date: November 17, 2025
- Time: 4:30 PM GMT (8:30 AM PST)
- Format: Presentation
- 8th Annual Evercore Healthcare Conference
- Date: December 3, 2025
- Time: 3:00 PM EST (12:00 PM PST)
- Format: Fireside chat
Both of these presentations serve as a platform for Kodiak Sciences to engage with investors and showcase the advancements made through their research. Attendees will gain insights into the company's innovative approach to developing potentially life-changing therapies.
About Kodiak Sciences Inc.
Kodiak Sciences is committed to pioneering retinal therapies aimed at combating blindness. The company's science-driven approach leverages their proprietary ABC® Platform, which uniquely combines protein-based and chemistry-based therapy disciplines. Through this technology, Kodiak is developing a robust portfolio of late-stage clinical programs.
Innovative Therapeutics and Clinical Programs
Currently, Kodiak Sciences is advancing two critical candidates, Tarcocimab and KSI-501, which are under evaluation in Phase 3 studies targeting retinal vascular diseases within a substantial marketplace valued at around $15 billion for anti-VEGF therapies. Additionally, KSI-101 is being studied in two separate Phase 3 trials focused on Macular Edema Secondary to Inflammation (MESI).
The Vision of Kodiak Sciences
At the heart of Kodiak Sciences is a relentless pursuit of innovation in retinal medicine. Their goal is to develop therapies that are not only groundbreaking but also accessible, thereby addressing pressing healthcare needs. The leadership team, spearheaded by Victor Perlroth, is dedicated to building a future where the treatments for eye diseases will vastly improve patient outcomes.
Stay Engaged with Kodiak Sciences
For those interested in following Kodiak Sciences' journey, a live webcast of the upcoming presentations will be available on the company’s official website. This event will provide an opportunity for stakeholders to engage more deeply with Kodiak's mission and advancements. The recordings will be accessible for a limited time post-event, ensuring that anyone who wishes to stay informed can easily do so.
Frequently Asked Questions
What is Kodiak Sciences focused on?
Kodiak Sciences specializes in developing innovative therapeutics for retinal diseases with the aim of preventing blindness.
When will Kodiak Sciences present at investor conferences?
Kodiak Sciences will present at the Jefferies Global Healthcare Conference on November 17, 2025, and the Evercore Healthcare Conference on December 3, 2025.
How can I access the presentation webcasts?
The live webcasts of the presentations will be available on Kodiak's official website in the 'Events and Presentations' section.
What are the key clinical programs being developed by Kodiak?
Kodiak is advancing Tarcocimab and KSI-501 in late-stage trials for retinal vascular diseases and KSI-101 for Macular Edema Secondary to Inflammation.
What distinguishes Kodiak's ABC® Platform?
Kodiak's ABC® Platform merges protein-based and chemistry-based therapies, allowing for the development of advanced retinal medicines.
